• Explore /
  • Poster
  • / Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with <em>RAS</em> wild-type tumors: The DEEPER trial (JACCRO CC-13).

Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).

Abstract Video & Slides Poster

Authors

null

Takanori Watanabe

Department of Surgery, Himeji Red Cross Hospital, Himeji, Japan

Takanori Watanabe , Akihito Tsuji , Manabu Shiozawa , Hirofumi Ota , Hironaga Satake , Taichi Yabuno , Junichi Hasegawa , Mitsugu Kochi , Dai Manaka , Tamotsu Sagawa , Masahito Kotaka , Yutaro Kubota , Yu Sunakawa , Takashi Sekikawa , Masato Nakamura , Masahiro Takeuchi , Wataru Ichikawa , Masashi Fujii

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Colorectal Cancer

Track

Colorectal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

UMIN000018217

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr 86)

DOI

10.1200/JCO.2021.39.3_suppl.86

Abstract #

86

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Hideaki Bando

First Author: Akihito Tsuji

First Author: Yu Sunakawa

First Author: Hironaga Satake